Emcure Pharmaceuticals
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
Emcure Pharmaceuticals vs Raymond Lifestyle Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Raymond Lifestyle
Raymond Lifestyle delivered a strong FY26 with total income of ₹7,034 crore (+11% YoY) and EBITDA of ₹804 crore (+23% YoY), marking the highest ever.
Result Snapshot
Revenue₹2,470 Cr₹1,776 Cr
PAT₹244 Cr₹-52 Cr
EBITDA Margin19.7%7%
Sentimentbullishbullish
Key Quotes
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.
We crossed 7,000 cr recording our highest ever total income of 7034 crores and 11% year-on-year growth.